Pulmonx has developed the Zephyr® Endobronchial Valve Therapy, a minimally invasive treatment for severe COPD/emphysema.
Visit https://uspatients.pulmonx.com/ for more. The one-time procedure is done during a simple bronchoscopy that require no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced.* Reducing hyperinflation and preventing air from getting trapped in the diseased parts of the lung allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath. Some patients treated report immediate relief and the ability to go back to doing everyday tasks with ease.**
The Zephyr® Valves were approved by the FDA in June 2018. Since 2007, more than 25,000 patients have been treated with the Zephyr® Valve worldwide**. The Zephyr® Valve is included in emphysema treatment guidelines issued by leading health organizations worldwide, including the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the UK’s National Institute for Health and Care Excellence (NICE). Important Safety Information: The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. Complications of treatment can include but are not limited to pneumothorax (tear in the lung), worsening of COPD symptoms, hemoptysis, pneumonia, and, in rare cases, death. The Zephyr® Valve is contraindicated in patients who have not quit smoking or are allergic to Nitinol (nickel-titanium). Please talk with your physician about other contraindications, warnings, precautions, and adverse events. Only a trained physician can decide whether a particular patient is an appropriate candidate for treatment with the Zephyr® Valve.
*The exact number of valves placed is based on physician discretion and patient anatomy.
**Criner G et al. Am J Respir Crit Care Med. 2018; 198 (9): 1151–1164.
11/15/2025
This November, Pulmonx teams across the globe joined together to walk in honor of COPD Awareness Month, raising awareness for those who fight to breathe every day.
Every step was a reminder of our mission: fighting every day, for every breath, so our patients don’t have to.
After years of struggling to breathe, read how Rebecca finally found relief through the Zephyr Valve procedure, a minimally invasive treatment that’s helped her regain her health and enjoy life again.
We are honored to share this heartfelt testimonial from one of Dr. Anurag Mehrotra's patients!
Rebecca Maness recently underwent a bronchoscopic lung volume reduction at Baptist Memorial Hospital-DeSoto. After several years of struggling to breathe, she feels both lucky and blessed to have taken a risk and have it work out for her.
The BLVR is a leading-edge, minimally invasive procedure for patients with severe emphysema who struggle with hyperinflated lungs and shortness of breath despite medications and oxygen therapy. Thanks to this procedure, Rebecca now feels the healthiest she has ever felt and enjoys doing things she thought she had lost forever.
Stories like Rebecca's remind us why our team members are devoted to helping develop healthier, stronger communities in the Mid-South, one patient at a time.
Happy World Lung Day 🫁 Today, we’re celebrating strides in pulmonology that are making a difference in helping people breathe easier and enjoy more of life’s everyday moments. Here’s to better breathing 🎉
Struggling with severe COPD or emphysema? The Zephyr Valve treatment may be the next step toward a fuller life. 🫁 Take our quiz today to see if it’s right for you. Here ➡️ bit.ly/4bBwEl3
08/13/2025
We understand the importance of insurance coverage so here’s a little breakdown. Learn more here bit.ly/4bsxMHq
08/05/2025
Before, Cindy struggled to walk across the yard. After treatment with Zephyr Valves, she was able to cook, shop, and enjoy more of life. 🫁
See how Zephyr Valves have helped people regain their lives here:
Get back to doing the things you love again just like Ralph. 🫁 Explore more experiences like this here bit.ly/4bBwEl3
Results May Vary.
07/08/2025
Struggling with severe COPD/Emphysema despite medication? Zephyr Valves may be the next step to help you breathe easier and live better.
Take our eligibility quiz today to see if it’s right for you. Link here. bit.ly/4bBwEl3
06/19/2025
After being diagnosed with lung cancer and smoking-related emphysema in 2016, Nancy struggled to breathe, making everyday tasks like carrying groceries and walking to the mailbox difficult. She was an ideal candidate for the bronchoscopic lung volume reduction (BLVR) procedure—a minimally invasive treatment performed by pulmonologist Jonathan Kurman, MD, and his team.
During the procedure, tiny valves are placed in the airways to block diseased parts of the lungs, reducing hyperinflation. This allows the healthier parts of the lungs to expand, relieving pressure on the diaphragm, decreasing shortness of breath, and making breathing easier.
Following her BLVR procedure with Dr. Kurman in January 2025, Nancy is breathing easier and enjoying her daily routine once again. “I can now walk my dog again—just weeks after the procedure. Thanks, Dr. Kurman!” Nancy shared.
Learn more about the BLVR procedure at froedtert.com/pulmonary-lung-care/emphysema.
Be the first to know and let us send you an email when Pulmonx posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Pulmonx has developed the Zephyr Endobronchial Valve Therapy, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done during a simple bronchoscopy that require no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation and preventing air from getting trapped in the diseased parts of the lung allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1 Patients treated report immediate relief and the ability to go back to doing everyday tasks with ease.
The Zephyr Valves were approved by the FDA in June 2018. Since 2007, more than 15,000 patients have been treated with the Zephyr Valve worldwide. The Zephyr Valve is included in emphysema treatment guidelines issued by leading health organizations worldwide, including the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the UK’s National Institute for Health and Care Excellence (NICE).
Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.1
1. Criner G et al AM J Resp Crit Care Med 2018, Published on 22-May-2018 as 10.1164/rccm.201803-0590OC
Brief Statement: The Pulmonx Zephyr®Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone, or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, or lobectomy; Congestive heart failure or recent myocardial infarction; FEV1